Sergej Konoplev

9.5k total citations
154 papers, 4.6k citations indexed

About

Sergej Konoplev is a scholar working on Hematology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, Sergej Konoplev has authored 154 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 78 papers in Hematology, 55 papers in Genetics and 44 papers in Pathology and Forensic Medicine. Recurrent topics in Sergej Konoplev's work include Acute Myeloid Leukemia Research (55 papers), Lymphoma Diagnosis and Treatment (43 papers) and Chronic Lymphocytic Leukemia Research (34 papers). Sergej Konoplev is often cited by papers focused on Acute Myeloid Leukemia Research (55 papers), Lymphoma Diagnosis and Treatment (43 papers) and Chronic Lymphocytic Leukemia Research (34 papers). Sergej Konoplev collaborates with scholars based in United States, China and Russia. Sergej Konoplev's co-authors include L. Jeffrey Medeiros, Marina Konopleva, Michael Andreeff, Hagop M. Kantarjian, Carlos E. Bueso‐Ramos, Jeffrey L. Jorgensen, Pei Lin, Wei Hu, A.Yu. Zaritskey and C. Cameron Yin and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Sergej Konoplev

146 papers receiving 4.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sergej Konoplev United States 35 2.2k 1.4k 1.4k 1.2k 1.1k 154 4.6k
Pei Lin United States 40 2.0k 0.9× 1.8k 1.3× 1.7k 1.2× 1.9k 1.6× 842 0.8× 224 5.4k
Keith Stockerl‐Goldstein United States 36 3.3k 1.5× 1.8k 1.3× 1.7k 1.2× 671 0.5× 1.4k 1.3× 200 5.2k
Stefan Hohaus Italy 39 1.5k 0.7× 1.4k 1.0× 1.4k 1.0× 591 0.5× 913 0.8× 167 4.2k
G.J. Ossenkoppele Netherlands 34 1.6k 0.7× 1.1k 0.8× 783 0.6× 677 0.5× 607 0.6× 84 3.3k
Thierry Lamy France 41 1.9k 0.8× 2.3k 1.6× 1.4k 1.0× 2.1k 1.7× 2.6k 2.4× 177 6.4k
Corrado Tarella Italy 41 2.5k 1.1× 2.8k 2.0× 1.0k 0.8× 1.5k 1.2× 1.3k 1.2× 213 6.2k
Lisa M. Rimsza United States 42 1.2k 0.5× 2.6k 1.9× 1.4k 1.0× 1.6k 1.2× 1.2k 1.2× 199 6.2k
Chor Sang Chim China 40 2.3k 1.1× 2.5k 1.8× 3.3k 2.4× 866 0.7× 1.1k 1.0× 240 6.8k
Kazimierz Kuliczkowski Poland 29 1.2k 0.6× 1.2k 0.9× 1.1k 0.8× 1.1k 0.9× 978 0.9× 202 3.5k
Marı́a José Calasanz Spain 43 2.2k 1.0× 866 0.6× 3.0k 2.2× 1.1k 0.9× 455 0.4× 153 5.1k

Countries citing papers authored by Sergej Konoplev

Since Specialization
Citations

This map shows the geographic impact of Sergej Konoplev's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sergej Konoplev with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sergej Konoplev more than expected).

Fields of papers citing papers by Sergej Konoplev

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sergej Konoplev. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sergej Konoplev. The network helps show where Sergej Konoplev may publish in the future.

Co-authorship network of co-authors of Sergej Konoplev

This figure shows the co-authorship network connecting the top 25 collaborators of Sergej Konoplev. A scholar is included among the top collaborators of Sergej Konoplev based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sergej Konoplev. Sergej Konoplev is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Sasaki, Koji, Farhad Ravandi, Tapan M. Kadia, et al.. (2022). Prediction of survival with intensive chemotherapy in acute myeloid leukemia. American Journal of Hematology. 97(7). 865–876. 13 indexed citations
3.
Sakhdari, Ali, Caleb A. Class, Guillermo Montalban‐Bravo, et al.. (2022). Immunohistochemical loss of enhancer of Zeste Homolog 2 (EZH2) protein expression correlates with EZH2 alterations and portends a worse outcome in myelodysplastic syndromes. Modern Pathology. 35(9). 1212–1219. 6 indexed citations
4.
5.
Konoplev, Sergej, Guilin Tang, Xiaoqiong Wang, et al.. (2021). Oligoblastic (<20%) Myeloid Neoplasms with KMT2A (MLL) Rearrangement Show Significant Overlap with Acute Myeloid Leukemia (AML) and Should be Regarded As AML. Blood. 138(Supplement 1). 793–793. 1 indexed citations
6.
Lyapichev, Kirill A., Guilin Tang, Shaoying Li, et al.. (2020). MYC expression is associated with older age, common morphology, increased MYC copy number, and poorer prognosis in patients with ALK+ anaplastic large cell lymphoma. Human Pathology. 108. 22–31. 10 indexed citations
7.
Lewis, Daniel J., Ramya Vangipuram, Uyen Ngoc Mui, et al.. (2019). The efficacy of omalizumab in Cutaneous Mastocytosis: A case series. Dermatologic Therapy. 32(3). e12848–e12848. 8 indexed citations
8.
Zeng, Zhihong, Natalia Baran, Sergej Konoplev, et al.. (2019). Targeting DHODH with AG-636 Induces Apoptosis and Differentiation and Inhibits Mitochondrial Function in AML, Translating into Anti-Tumor Efficacy in Vitro and in Vivo. Blood. 134(Supplement_1). 3911–3911. 2 indexed citations
9.
Jain, Preetesh, Rashmi Kanagal‐Shamanna, Sergej Konoplev, Zhuang Zuo, & Zeev Estrov. (2018). Biclonal IGHV‐4‐34 hairy cell leukemia variant and CLL ‐ successful treatment with ibrutinib and venetoclax. American Journal of Hematology. 93(12). 1568–1569. 24 indexed citations
10.
Pemmaraju, Naveen, Hagop M. Kantarjian, Joseph D. Khoury, et al.. (2017). Long-Term Outcomes in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Blood. 130. 3855–3855. 5 indexed citations
11.
Audette, Charlene A., Yelena Kovtun, Naval Daver, et al.. (2017). CD123 Expression Patterns and Potential of IMGN632, a CD123-Targeted Antibody Drug Conjugate, in Acute Lymphoblastic Leukemia. Blood. 130. 2718–2718. 2 indexed citations
12.
Cho, Byung-Sik, Zhihong Zeng, Hong Mu, et al.. (2015). Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy. Blood. 126(2). 222–232. 95 indexed citations
13.
Shen, Qi, Juan Ouyang, Guilin Tang, et al.. (2014). Flow cytometry immunophenotypic findings in chronic myelomonocytic leukemia and its utility in monitoring treatment response. European Journal Of Haematology. 95(2). 168–176. 24 indexed citations
14.
Hong, David S., Razelle Kurzrock, Jeffrey G. Supko, et al.. (2012). A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas. Clinical Cancer Research. 18(12). 3396–3406. 197 indexed citations
15.
Curry, Choladda V., Sergej Konoplev, Carlos A. Torres‐Cabala, et al.. (2012). Blastic Plasmacytoid Dendritic Cell Neoplasm With Leukemic Progression. Journal of Medical Cases. 3(6). 337–339. 1 indexed citations
16.
Zeng, Zhihong, Yue Shi, Ismael Samudio, et al.. (2008). Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood. 113(24). 6215–6224. 397 indexed citations
17.
Olsen, Randall J., Dennis P. O’Malley, Sergej Konoplev, et al.. (2007). The role of Janus Kinase 2 V617F mutation in extramedullary hematopoiesis of the spleen in neoplastic myeloid disorders. Modern Pathology. 20(9). 929–935. 24 indexed citations
18.
García, M. García, Sergej Konoplev, Cristian Morosan, et al.. (2007). MALT Lymphoma Involving the Kidney. American Journal of Clinical Pathology. 128(3). 464–473. 26 indexed citations
19.
Sun, Kai, Minghui Li, Marina Konopleva, et al.. (2007). The Synthetic Triterpenoid, CDDO, Suppresses Alloreactive T Cell Responses and Reduces Murine Early Acute Graft-versus-Host Disease Mortality. Biology of Blood and Marrow Transplantation. 13(5). 521–529. 10 indexed citations
20.
Hong, David S., Razelle Kurzrock, Jeffrey G. Supko, et al.. (2007). Phase I trial with a novel orally administered synthetic triterpenoid RTA 402 (CDDO-Me) in patients with solid tumors and lymphoid malignancies. Molecular Cancer Therapeutics. 6. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Pei Lin Breakdown of academic impact, for papers by Keith Stockerl‐Goldstein Breakdown of academic impact, for papers by Stefan Hohaus Breakdown of academic impact, for papers by G.J. Ossenkoppele Breakdown of academic impact, for papers by Thierry Lamy Breakdown of academic impact, for papers by Corrado Tarella Breakdown of academic impact, for papers by Lisa M. Rimsza Breakdown of academic impact, for papers by Chor Sang Chim Breakdown of academic impact, for papers by Kazimierz Kuliczkowski Breakdown of academic impact, for papers by Marı́a José Calasanz
Rankless by CCL
2026